RecruitingNCT02673996

POTS Adrenergic Ab (CIHR Aims #1&2)

The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)

Sponsor

University of Calgary

Enrollment

125 participants

Start Date

Jan 1, 2016

Study Type

OBSERVATIONAL

Conditions

Postural Tachycardia Syndrome

Summary

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Isoproterenol and a drug called Phenylephrine for people with postural tachycardia syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.